Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezafungin SC Safety and PK in Healthy Adults
NCT04117607Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2019
- Primary completion
- May 2020
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rezafungin in candidemia and invasive candidiasis (12 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants With Unsolicited Adverse Events, Number of Participants With Abnormal Chemistry Laboratory Toxicity Results and 12 more. Started Dec 2019; status: terminated.
02
Drugs
rezafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on NCT04117607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04117607.